7UPJ

HIV-1 PROTEASE/U101935 COMPLEX


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Work: 0.208 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.

Skulnick, H.I.Johnson, P.D.Aristoff, P.A.Morris, J.K.Lovasz, K.D.Howe, W.J.Watenpaugh, K.D.Janakiraman, M.N.Anderson, D.J.Reischer, R.J.Schwartz, T.M.Banitt, L.S.Tomich, P.K.Lynn, J.C.Horng, M.-M.Chong, K.-T.Hinshaw, R.R.Dolak, L.A.Seest, E.P.Schwende, F.J.Rush, B.D.Howard, G.M.Toth, L.N.Wilkinson, K.F.Kakuk, T.J.Johnson, C.W.Cole, S.L.Zaya, R.M.Zipp, G.L.Possert, P.L.Dalga, R.J.Zhong, W.-Z.Williams, M.G.Romines, K.R.

(1997) J.Med.Chem. 40: 1149-1164

  • DOI: 10.1021/jm960441m
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Recently, cyclooctylpyranone derivatives with m-carboxamide substituents (e.g. 2c) were identified as potent, nonpeptidic HIV protease inhibitors, but these compounds lacked significant antiviral activity in cell culture. Substitution of a sulfonamid ...

    Recently, cyclooctylpyranone derivatives with m-carboxamide substituents (e.g. 2c) were identified as potent, nonpeptidic HIV protease inhibitors, but these compounds lacked significant antiviral activity in cell culture. Substitution of a sulfonamide group at the meta position, however, produces compounds with excellent HIV protease binding affinity and antiviral activity. Guided by an iterative structure-based drug design process, we have prepared and evaluated a number of these derivatives, which are readily available via a seven-step synthesis. A few of the most potent compounds were further evaluated for such characteristics as pharmacokinetics and toxicity in rats and dogs. From this work, the p-cyanophenyl sulfonamide derivative 35k emerged as a promising inhibitor, was selected for further development, and entered phase I clinical trials.


    Related Citations: 
    • Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
      Skulnick, H.I.,Johnson, P.D.,Howe, W.J.,Tomich, P.K.,Chong, K.-T.,Watenpaugh, K.D.,Janakiraman, M.N.,Dolak, L.A.,Mcgrath, J.P.,Lynn, J.C.,Horng, M.-M.,Hinshaw, R.R.,Zipp, G.L.,Ruwart, M.J.,Schwende, F.J.,Zhong, W.-Z.,Padbury, G.E.,Dalga, R.J.,Shiou, L.,Possert, P.L.,Rush, B.D.,Wilkinson, K.F.,Howard, G.M.,Toth, L.N.,Williams, M.G.,Kakuk, T.J.,Cole, S.L.,Zaya, R.M.,Lovasz, K.D.,Morris, J.K.,Romines, K.R.,Thaisrivongs, S.,Aristoff, P.A.
      (1995) J.Med.Chem. 38: 4968


    Organizational Affiliation

    Discovery Chemistry Research, Pharmacia and Upjohn, Kalamazoo, Michigan 49001, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
HIV-1 PROTEASE
A, B
99Human immunodeficiency virus type 1 group M subtype BMutation(s): 0 
Gene Names: gag-pol
Find proteins for P03367 (Human immunodeficiency virus type 1 group M subtype B)
Go to UniProtKB:  P03367
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
INU
Query on INU

Download SDF File 
Download CCD File 
A
N-(3-CYCLOPROPYL(5,6,7,8,9,10-HEXAHYDRO-2-OXO-2H-CYCLOOCTA[B]PYRAN-3-YL)METHYL)PHENYLBENZENSULFONAMIDE
C27 H29 N O5 S
GDRNWAKVNIROCG-DEOSSOPVSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
INUKi: 3 - 3.2 nM (98) BINDINGDB
INUKi: 3.2 nM BINDINGMOAD
INUKi: 3.2 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Work: 0.208 
  • Space Group: P 21 21 2
Unit Cell:
Length (Å)Angle (°)
a = 60.374α = 90.00
b = 89.605β = 90.00
c = 47.341γ = 90.00
Software Package:
Software NamePurpose
XENGENdata reduction
CEDARrefinement
XENGENdata scaling
MERLOTphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 1997-04-21
    Type: Initial release
  • Version 1.1: 2008-03-25
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2012-02-22
    Type: Database references